Immunovaccine Inc.(TSX-V:IMV), a vaccine development company, announced today that it has signed a collaborative agreement with the Dana-Farber Cancer Institute, a principal teaching affiliate of the Harvard Medical School.
The research collaboration involves formulating Dana-Farber’s HIV protein antigens in Immunovaccine’s DepoVax™ vaccine enhancement and delivery platform. The goal of this preclinical research is to establish whether this novel vaccine formulation will induce a stronger immune response.
“Dana-Farber is a leader in vaccine research and this collaboration presents an exciting opportunity to evaluate new antigens formulated in our DepoVax™ vaccine delivery platform," said Dr. Marc Mansour, vice president of R&D at Immunovaccine. “We are hopeful this research will lead to new and expanded opportunities for our vaccine delivery platform.”
Dana-Farber Cancer Institute (WWW.DANA-FARBER.ORG) is a principal teaching affiliate of the Harvard Medical School and a federally designated Center for AIDS Research. It is also a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC) and designated comprehensive cancer center by the National Cancer Institute.
Immunovaccine Inc. (TSX-V:IMV) is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax™ vaccine delivery technology and product candidates. The company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines. WWW.IMVACCINE.COM
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information, contact:
Dr. Marc Mansour, Vice President R&D, Immunovaccine Inc.
Jennifer Ayotte, Director Communications, Immunovaccine Inc.
Andrew Mielach, Tiberend Strategic Advisors, Inc.
Halifax, Nova Scotia, April 22, 2010